Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

OBJECTIVES: To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) from Japan and South Korea. METHODS: In this phase III, open-label continuation study (BEL114333; NCT01597622), eligible completers of BEL113750 (NCT01345253) or BEL112341 (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Bae, Sang-Cheol, Bass, Damon, Curtis, Paula, Chu, Myron, DeRose, Kathleen, Ji, Beulah, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256836/
https://www.ncbi.nlm.nih.gov/pubmed/34215703
http://dx.doi.org/10.1136/rmdopen-2021-001629

Ejemplares similares

Ejemplares similares